Despite the introduction of new medicinal agents for the treatment of
vertigo, no new pharmacological entities have been established. For se
veral years all ''new'' products have belonged to the well established
pharmacological classes of antihistamines (H-1-antagonists), calcium-
entry inhibitors or vasodilators. In this article these pharmacologica
l classes will be briefly reviewed, with special emphasis given to the
pre-synaptic histamine receptor (H,), a recently established pharmaco
logical function. Compounds interfering with this receptor, especially
the antagonists, seem to offer new ways of treating vertigo and possi
bly also new ways of developing new therapeutic agents.